These low levels of PRMT6 lead to reduction of the repressive H3R2me2a modifications in the promoter region of G6PD resulting in the enhanced expression of G6PD which contributes to the paclitaxel resistance of the ovarian cancer cells [174]. The gene discussed is PRMT6; the disease is ovarian carcinoma.